Consultant Physician

Recommendations

Info

Impact of Intensive Therapy for Diabetes: Summary of Major Clinical Trials Study Microvasc CVD Mortality UKPDS/PSM DCCT / EDIC* ACCORD ADVANCE VADT Kendall ) DM, Bergenstal RM. © International Diabetes Center 2009 UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854. Holman RR et al. N Engl J Med. 2008;359:1577. DCCT Research Group. N Engl J Med 1993;329;977. Nathan DM et al. N Engl J Med. 2005;353:2643. Gerstein HC et al. N Engl J Med. 2008;358:2545. Patel A et al. N Engl J Med 2008;358:2560. Duckworth W et al. N Engl J Med 2009;360:129. (erratum: Moritz T. N Engl J Med 2009;361:1024 Initial Trial Long Term Follow-up * in T1DM
A Patient- Centered Approach to Type 2 Diabetes Treatment strategies should be made taking into consideration the needs , preferences, and tolerances of each patient. Currently 13 classes of FDA-approved antidiabetic agents for type 2 diabetes Managing cardiovascular risk factors is a major focus of therapy Iamail-Beigi F, et al. Ann Intern Med 2011;154:554-559. Inzucchi SE, et al.Diabetes Care . 2012;35:1364-1379. Inzucchi SE, et al. Diabetologia. 2012;55:1577-1596.
Page 1 and 2:
Credibility and Evidence Based Natu
Page 3 and 4:
Aim of presentation • How far the
Page 5 and 6:
The relationship between exposure t
Page 7 and 8:
Conflict of interest (COI) The trad
Page 9 and 10:
Candidate List of Categories of Fin
Page 11 and 12:
Actual or reasonably perceived conf
Page 13 and 14:
Physician relationships with the in
Page 15 and 16:
Physician Relationships With The In
Page 17 and 18:
Physician Relationships With The In
Page 19 and 20:
Concerns Regarding Physician Relati
Page 21 and 22:
Ethics And Compliance Payments to
Page 23 and 24:
Ethics And Compliance Biopharmaceut
Page 25 and 26:
Guidelines For Physician-Pharmaceut
Page 27 and 28:
Financial Conflicts of Interest Che
Page 29 and 30:
Page 31 and 32:
Page 33 and 34: Drug surveillance and a real world
Page 35 and 36: Systems for assessment of postmarke
Page 37 and 38: Systems for assessment of postmarke
Page 39 and 40: Exposures to information from pharm
Page 41 and 42: Why we as prescribers still meet ph
Page 43 and 44: This is how each of the companies l
Page 45 and 46: After two decades of decimation, on
Page 47 and 48: Incretin Drugs Contribute Heavily t
Page 49 and 50: A Clouded Future For Big Pharma's B
Page 51 and 52: The largest health fraud settlement
Page 53 and 54: Use of drugs and its budgetary impl
Page 55 and 56: Key functions of drug regulatory ag
Page 57 and 58: Relationships Between Authors of Cl
Page 59 and 60: Conflicts (Dualities) of interest i
Page 61 and 62: Conflicts (Dualities) of interest a
Page 63 and 64: Cross-sectional survey of 192 autho
Page 65 and 66: Clinical practice guidelines for di
Page 67 and 68: Hierarchy of evidence-based medicin
Page 69 and 70: Criteria for assigning levels of ev
Page 71 and 72: Criteria for assigning grades of re
Page 73 and 74: Criteria for assigning levels of ev
Page 75 and 76: Meta-analysis may not consider COI
Page 77 and 78: Financial disclosures in RCT’s* 5
Page 79 and 80: Large trials that compared clinical
Page 81 and 82: HBA1C targets suggested by differen
Page 83: The goal for A1c may not be safely
Page 87 and 88: According to subset analyses from a
Page 89 and 90: Approach to management of hyperglyc
Page 91 and 92: VA/DoD Clinical Practice Guideline
Page 93 and 94: What is Algorithm (in guidelines)?
Page 95 and 96: Types of medical practice setting
Page 97 and 98: In summary why we need clinical pra
Page 99 and 100: Dissemination and implementation an
Page 101 and 102: Clinical Practice Guidelines (CPGs)
Page 107 and 108: Personalized medicine Using a pers
Page 109 and 110: Delaying the Onset of Type 2 Diabet
Page 111 and 112: Intervention studies on the prevent
Page 113 and 114: Management of hyperglycaemia in typ
Page 115 and 116: General recommendations for managem
Page 117 and 118: ADA-EASD Position Statement: Manage
Page 119 and 120: Management of Hyperglycemia in T2DM
Page 121 and 122: AACE/ACE* Diabetes Algorithm For Gl
Page 123 and 124: Dr. Alashbal’ s observation regar
Page 133 and 134: Management of hyperglycemia in type
Page 135 and 136:
Relevant comments on ADA/EASD algor
Page 137 and 138:
ADA-EASD Position Statement: Manage
Page 139 and 140:
Page 141 and 142:
Page 144 and 145:
Sequential insulin strategies in ty
Page 146 and 147:
ADA/EASD position statement 2012 In
Page 148 and 149:
ADA/EASD position statement 2012 L
Page 150 and 151:
Individualization of therapy ADA/EA
Page 152 and 153:
NICE Type 2 diabetes algorithm for
Page 154 and 155:
Relevant comments on NICE algorithm
Page 156 and 157:
Relevant comments on SIGN algorithm
Page 158 and 159:
Relevant comments on DoD/VA algorit
Page 160 and 161:
Comparison of the ADA/EASD algorith
Page 162 and 163:
Comparison of the ADA/EASD algorith
Page 164 and 165:
Pharmacotherapy of Type 2 Diabetes
Page 166 and 167:
Maximum blood glucose lowering effe
Page 168 and 169:
Dose-response relationships of sulp
Page 170 and 171:
Hazard ratios (95% CI) for differen
Page 172 and 173:
"metformin, sulfonylureas, • •
Page 174 and 175:
Efficacy of monotherapy Drug Thiazo
Page 176 and 177:
Insulin is the most effective diabe
Page 178 and 179:
Burdens of insulin therapy as a fir
Page 180 and 181:
Why health care providers and patie
Page 182 and 183:
Page 184 and 185:
The maximum period after which we m
Page 186 and 187:
Doctor, patient, and system barrier
Page 188 and 189:
Painful truth and big question why
Page 190 and 191:
Report of Institute for Quality and
Page 192 and 193:
Report of Institute for Quality and
Page 194 and 195:
Insulin glargine vs. NPH insulin In
Page 196 and 197:
Safety of Incretin-Based Therapies
Page 198 and 199:
The use of incretin-based glucose-l
Page 200 and 201:
Dr. Alashbal’ s observation regar
Page 202 and 203:
Conclusions The pendulum is swingin
Page 204 and 205:
Suggested seven deadly sins of drug
Page 206 and 207:
Never be And the first, this sin is
Page 208:
hank you Dr. Abdulameer Abdullah Al
show all

Consultant Physician

Create successful ePaper yourself

Delete template?

Save as template?